10 Year Follow-Up of Aortic Valve Replacement Outcomes Stratified by Type and Brand of Valve

Abstract

in 2pts and zone 3 in 4 pts. One patient died perioperatively (6%) of ongoing mesenteric ischemia. No patient showed recurrent thromboembolism. One pt required TEVAR explant one month postoperatively for device infection. Five-year survival was 78% with two late nonvascular deaths (lung neoplasia and complication from Crohn disease). A thrombophilia syndrome or neoplasia was diagnosed in 9/17 (52.9%) pre or postoperatively. CONCLUSION: Thoracic FFAT is rare and can involve any aortic segment. Thrombus size and location are key to establish the operative strategy. TEVAR seems a safe alternative to a standard open surgery in presence of adequate proximal and distal landing sites. Freedom from late FFAT recurrence is excellent regardless of the surgical approach. Postoperative thrombophilia and cancer screening is mandatory.